Kristin VanderPas

Cooley advised the underwriters of Septerna, a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, on its upsized $331.2 million initial public offering.

Cooley advised the underwriters of Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, on its upsized $293 million initial public offering.

Cooley advised TD Cowen and Cantor, the placement agents on Palvella Therapeutics’ definitive merger agreement with Pieris Pharmaceuticals and concurrent oversubscribed $78.9 million private financing.

Cooley advised the underwriters of Viking Therapeutics – a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders – on its $632.5 million public offering of common stock.